These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 12654762)
1. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762 [TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. Odenholt I; Cars O J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293 [TBL] [Abstract][Full Text] [Related]
3. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. Deryke CA; Du X; Nicolau DP J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688 [TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Schafer J; Hovde LB; Simonson D; Rotschafer JC Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998 [TBL] [Abstract][Full Text] [Related]
6. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677 [TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296 [TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740 [TBL] [Abstract][Full Text] [Related]
10. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041 [TBL] [Abstract][Full Text] [Related]
11. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. Schentag JJ J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae. Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764 [TBL] [Abstract][Full Text] [Related]
15. Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum. Bowker KE; Garvey MI; Noel AR; Tomaselli SG; Macgowan AP J Antimicrob Chemother; 2013 May; 68(5):1130-8. PubMed ID: 23361641 [TBL] [Abstract][Full Text] [Related]
16. Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. Garrison MW J Antimicrob Chemother; 2003 Sep; 52(3):503-6. PubMed ID: 12917240 [TBL] [Abstract][Full Text] [Related]
17. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Lister PD Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827 [TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. Homma T; Hori T; Sugimori G; Yamano Y Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314 [TBL] [Abstract][Full Text] [Related]
20. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. MacGowan AP; Rogers CA; Holt HA; Bowker KE Antimicrob Agents Chemother; 2003 Mar; 47(3):1088-95. PubMed ID: 12604546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]